Laurie Wesolowicz, PharmD, director, pharmacy services clinical, Blue Cross Blue Shield of Michigan (BCBSM), says that clinical evidence and other factors can drive formulary decision-making. Evidence can influence the value and coverage recommendations for drugs covered under the pharmacy (formulary) and medical benefits.
Laurie Wesolowicz, PharmD, director, pharmacy services clinical, Blue Cross Blue Shield of Michigan (BCBSM), says that clinical evidence and other factors can drive formulary decision-making. Evidence can influence the value and coverage recommendations for drugs covered under the pharmacy (formulary) and medical benefits.
In particular, she addresses BCBSM’s formulary decision-making structure, which includes the BCBSM/Blue Care Network (BCN) Pharmacy and Therapeutics Committee. The Committee is comprised of a Clinical Core Workgroup, Blue Cross Blue Shield, BCN HMO, BCBSM Medicare Part D, a Specialty Drug Workgroup, and BCN Medicare Part D.
Dr Wesolowicz also suggests that comparative effectiveness research can influence the overall assessment of a given drug’s safety and quality for formulary and coverage decisions. She adds that there is a growing focus on evidence-based decision-making, especially in administration of high-cost specialty drugs. Other coverage decision-making challenges include the site of care, employer group pressures for cost-containment, the Affordable Care Act marketplace, and Centers for Medicare & Medicaid Services Medicare Part D rules.
She notes that the old models of pharmacy and therapeutics decision-making processes focus on comparing the effectiveness, safety, and expense of new drugs against older drugs in the same class. Newer models ask questions such as:
Dr Wesolowicz says that value-based healthcare delivery will require a multi-stakeholder vision for innovation. Dr Wesolowicz asks, “What’s really a value?” A common definition of value, according to Dr Wesolowicz, “will be the way to produce better outcomes for patients.” For instance, the Christiana Care Health System in Delaware has developed a “value framework” that evaluates new specialty medications. Like BCBSM, they leverage a committee to guide decision-making. They also use scorecards to assess efficacy, risk, cost, and societal benefit of medications. These specific indicators identify a medication’s “value score.”
She suggests that new tools such as these will assist health plans and systems in evaluating clinical evidence of new and emerging drugs in formulary decision-making. “We are going to have to come up with a common framework to evaluate evidence,” says Dr Wesolowicz.
Rapid FDA approval and coverage decisions on Medicare Part D medications, the need for real-world data in evidence, rapid communication of clinical findings, and more will continue to challenge formulary decision-making.
Age Alone Is No Barrier to Allo-HCT for AML, Data Indicate
April 17th 2024A new study is among the largest real-world analyses to date to assess trends over time and predictive factors for older patients with acute myeloid leukemia (AML) who received allogeneic hematopoietic cell transplantation (allo-HCT).
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Need for Pharmacogenomic Testing in Mental Health Care Explored at AMCP 2024
April 17th 2024Presenters from the Mayo Clinic discussed the benefits of implementing pharmacogenomic testing in mental health care for the betterment of patient outcomes, reducing medical costs, and more at the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen